Publication | Open Access
734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial
28
Citations
0
References
2006
Year
Accelerate TrialHepatologyPeginterferon Alpha-2aViral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyHcv Genotype 2Antiviral DrugMedicine
No additional data available for this publication yet. Check back later!